Studie zur Therapie von Kindern mit Glioblastomen.

Beteiligte Wissenschaftler und Funktion:
Statistische Planung und statistische Ausertung
Univ.-Prof. Dr. rer. nat. et med. habil. Andreas Faldum
Dr.  rer. nat.  Robert Kwiecien

Kooperationspartner:
Univ.-Prof. Dr. C. Kramm, Universitätsmedizin Göttingen (Studienleitung)

Förderung:
Deutsche Kinderkrebsstiftung

Ziel der Studie:
To confirm that the Event-Free Survival (EFS) in patients ≥ 3 and < 18 years of age with WHO
grade IV/CNS WHO grade 4 and WHO grade III/CNS WHO grade 3 diffuse high grade gliomas
as well as diffuse high grade gliomas without a distinct grade, DIPG (as confirmed by radiology),
and gliomatosis cerebri (as confirmed by radiology) differs for children treated with temozolomide
radiochemotherapy AND additional VPA compared to children in the historic HIT-HGG-2007
sample treated with temozolomide radiochemotherapy only.